- Home
- BZAIW vs WGSWW Comparison
BZAIW vs WGSWW Comparison
Compare BZAIW & WGSWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZAIW
- WGSWW
- Stock Information
- Founded
- BZAIW 2010
- WGSWW 2017
- Country
- BZAIW United States
- WGSWW United States
- Employees
- BZAIW 232
- WGSWW 1000
- Industry
- BZAIW
- WGSWW Retail: Computer Software & Peripheral Equipment
- Sector
- BZAIW
- WGSWW Technology
- Exchange
- BZAIW Nasdaq
- WGSWW Nasdaq
- Market Cap
- BZAIW N/A
- WGSWW N/A
- IPO Year
- BZAIW N/A
- WGSWW N/A
- Fundamental
- Price
- BZAIW $0.53
- WGSWW $0.07
- Analyst Decision
- BZAIW
- WGSWW
- Analyst Count
- BZAIW 0
- WGSWW 0
- Target Price
- BZAIW N/A
- WGSWW N/A
- AVG Volume (30 Days)
- BZAIW 233.5K
- WGSWW 36.6K
- Earning Date
- BZAIW 05-14-2025
- WGSWW 02-18-2025
- Dividend Yield
- BZAIW N/A
- WGSWW N/A
- EPS Growth
- BZAIW N/A
- WGSWW N/A
- EPS
- BZAIW N/A
- WGSWW N/A
- Revenue
- BZAIW $1,967,000.00
- WGSWW $305,450,000.00
- Revenue This Year
- BZAIW N/A
- WGSWW N/A
- Revenue Next Year
- BZAIW N/A
- WGSWW N/A
- P/E Ratio
- BZAIW N/A
- WGSWW N/A
- Revenue Growth
- BZAIW N/A
- WGSWW 50.79
- 52 Week Low
- BZAIW $0.42
- WGSWW $0.17
- 52 Week High
- BZAIW $0.57
- WGSWW $0.21
- Technical
- Relative Strength Index (RSI)
- BZAIW 37.03
- WGSWW 38.15
- Support Level
- BZAIW $0.49
- WGSWW $0.06
- Resistance Level
- BZAIW $1.05
- WGSWW $0.08
- Average True Range (ATR)
- BZAIW 0.11
- WGSWW 0.01
- MACD
- BZAIW -0.04
- WGSWW -0.00
- Stochastic Oscillator
- BZAIW 6.89
- WGSWW 5.80
About BZAIW Blaize Holdings Inc. Warrants
Blaize Holdings Inc provides customized, programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company is a semiconductor and software technology company dedicated to revolutionizing the world of AI.
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.